Legislation Aims to Combat Loneliness in the U.S.
Recent legislative efforts in Washington, D.C., seek to address the growing concern of loneliness and social isolation among Americans, particularly older adults. In June, Senator Chris Murphy, a Democrat from Connecticut, introduced two significant bills aimed at tackling this issue.
The first proposal, the Addressing Social Isolation and Loneliness in Older Adults Act, would allocate $62.5 million annually to community organizations for outreach and support services tailored to senior citizens. These individuals often face challenges in maintaining social connections due to health issues and limited mobility.
The second initiative, the National Strategy for Social Connection Act, proposes increased funding for the Centers for Disease Control and Prevention (CDC) to enhance research on loneliness and connection strategies. It also aims to establish an Office of Social Connection Policy within the executive branch to provide guidance to the President. Murphy has noted the importance of addressing loneliness, labeling it a public health crisis and a critical issue for democracy.
Andrew MacPherson, chair of the Foundation for Social Connection Action Network, highlighted the drastic change in attention given to this issue over the past decade, with significant efforts now being made at the federal level.
Exploring Medication as a Potential Solution for Loneliness
In addition to legislative measures, researchers are investigating pharmacological approaches to mitigate loneliness. Stephanie Cacioppo, a behavioral neuroscientist, initiated a clinical trial in 2017 to examine the effects of pregnenolone, a hormone related to the adrenal gland, on loneliness. Pregnenolone is known for its neurosteroid properties that can influence brain cell communication.
Cacioppo’s research indicated that loneliness can alter brain functions, particularly affecting the amygdala, which plays a role in fear response and emotional regulation. Elevated fear of social situations can lead to further isolation, creating a cycle that exacerbates loneliness.
Preliminary results from the trial suggested that pregnenolone might reduce fears associated with social interactions. However, Cacioppo paused the study in 2019, citing concerns over potential side effects, including disruptions in sleep and cardiovascular health. Following the loss of her husband, a noted loneliness researcher, Cacioppo became increasingly aware of the personal impact of isolation and has since advocated for natural remedies like outdoor exercise to alleviate loneliness.
While pharmacological advancements are still under investigation, the ongoing legislative efforts and scientific inquiries reflect a growing recognition of the need to address loneliness in society.
